Letermovir
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Letermovir: Vulvovaginal candidiasis
One-Sentence Summary
Letermovir is an antiviral originally used for cytomegalovirus (CMV) infection. The TxGNN model predicts it may be effective for vulvovaginal candidiasis, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the computational model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Vulvovaginal candidiasis |
| TxGNN Prediction Score | 0.9988 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Letermovir is a CMV-specific antiviral, and its efficacy in CMV infection is the basis for its approval. Its known mechanism is inhibition of the viral terminase complex (pUL56/pUL51/pUL89).
This target is not present in fungi such as Candida species, so no plausible link to antifungal activity is supported. The very high TxGNN score (0.9988) is a computational prediction only. It is probably driven by network-level associations, for example letermovir’s many drug interactions and its co-prescription with azole antifungals in transplant patients. It should not be read as biological evidence.
Any benefit would be speculative, such as an indirect effect through fewer immunosuppression-related complications, and none is documented. Similarity between the original and predicted indications, and route compatibility, have not been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02469367 | PREVYMIS | Not specified | Not specified |
| 02469375 | PREVYMIS | Not specified | Not specified |
| 02469383 | PREVYMIS | Not specified | Not specified |
Safety Considerations
- Drug Interactions: 100 interactions were found in the interaction databases. The first 20 records reviewed include:
- Major: Eliglustat, Naloxegol, Cisapride
- Moderate: Hydrocortisone, Pioglitazone, Aprepitant, Triamcinolone, Omeprazole, Dexamethasone, Betamethasone, Budesonide (including nasal), Chlorpropamide, Clarithromycin, Saxagliptin, Glimepiride, Naldemedine, Lansoprazole, Acetohexamide, Nitisinone
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score. No clinical trials or publications exist, and letermovir’s known target (the CMV terminase complex) is absent from fungi. A biologically plausible link is lacking, and the safety review cannot proceed without the Health Canada label.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data, for example from DrugBank
- Any preclinical evidence of anti-Candida activity, such as in vitro susceptibility data
- A literature and trial search for evidence of benefit in vulvovaginal candidiasis
- Assessment of route compatibility and dosage forms for a vulvovaginal indication
- Review of the interaction profile, especially the major interactions, for the likely patient population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.